ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

ADMA Biologics, Inc.NASDAQ: ADMA

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$2.13M, compared with $18.66M a year earlier. Trailing-twelve-month net change in cash was $45.74M.

Context

  • Net change in cash amounted to 3.0% of revenue in FY2025, down 9.1 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near -$2.13M or moves back toward the trailing-twelve-month quarterly average of $11.43M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.13M-104.2% QoQ
Last fiscal yearDec 2025
-$15.52M-130.0% YoY
LTMJun 2026
$45.74M+2140.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-111.4%——
1 year-130.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(15.52M) USD
Year-over-year change
-130.0%

Net Change in Cash vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2140.8% is the highest of 4, against a peer median of +121.9%.
  • Net change in cash amounts to 8.9% of revenue for ADMA, versus a peer median of 7.0%.
ADMA Competitors
Net Change in Cash for ADMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$136.08M USD+196.3%—243.6%
GRFSGrifols, S.A.LTM Jun 2026€61.77M EUR-96.0%-73.7%0.8%
ADMAADMA Biologics, Inc.LTM Jun 2026$45.74M USD+2140.8%—8.9%
ABUSArbutus Biopharma CorporationLTM Mar 2026$13.37M USD+121.9%-38.4%7.0%
Peer median (excluding ADMA) —+121.9%-56.1%7.0%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
Deferred Income Tax220.76K00(84.28M)11.02M
Stock-Based Compensation3.49M5.22M6.19M13.62M20.03M
Change in Working Capital(51.68M)(18.29M)(10.12M)(18.54M)(139.6M)
Accounts Receivables(15.34M)13.07M(11.92M)(22.58M)(108.43M)
Inventory(43.19M)(38.56M)(9.63M)2.67M(36.23M)
Accounts Payables1.36M799.98K3.84M4.15M2.33M
Other Working Capital5.49M6.4M7.58M(2.78M)2.74M
Other Non-Cash Items1.75M12.35M32.64M2.16M3.92M
Operating Cash Flow(112.37M)(59.51M)8.8M118.67M50.4M
Capital Expenditures(13.51M)(13.91M)(4.98M)(8.58M)(22.58M)
Acquisitions (Net)00001M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(210K)(349K)(316K)
Investing Cash Flow(13.51M)(13.91M)(4.98M)(8.58M)(21.89M)
Debt Repayment(34K)51.71M(23.6M)(60M)(3.18M)
Common Stock Issued121.14M64.65M07.49M2.98M
Common Stock Repurchased00(1.42M)0(31.94M)
Dividends Paid00000
Other Financing Activities(62K)(7.51M)(13.97M)(5.8M)(11.89M)
Financing Cash Flow121.05M108.85M(38.99M)(58.3M)(44.02M)
Effect of Forex Changes00000
Net Change in Cash(4.83M)35.43M(35.17M)51.8M(15.52M)
Free Cash Flow(125.88M)(73.42M)3.82M110.1M27.82M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.